Nova Leap Health Corp.
NVLPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.74 | 0.13 | 1.25 |
| FCF Yield | 7.92% | 14.83% | 6.06% | 6.30% |
| EV / EBITDA | 16.06 | -44.17 | 50.05 | 10.45 |
| Quality | ||||
| ROIC | 3.16% | 1.81% | -3.25% | -3.53% |
| Gross Margin | 38.38% | 37.31% | 35.37% | 33.89% |
| Cash Conversion Ratio | 1.01 | -2.04 | -1.22 | 1.24 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.98% | 7.15% | 17.67% | 6.93% |
| Free Cash Flow Growth | -35.91% | 123.97% | -56.44% | -27.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.98 | -1.50 | 7.35 | 1.20 |
| Interest Coverage | 8.08 | 3.18 | -3.92 | -3.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 137,064.93 | 36,351.27 |
| Cash Conversion Cycle | -9.27 | -1.92 | 7.77 | 41.46 |